Myriad Data Suggests ctDNA Testing Could Refine Ovarian Cancer Recurrence Prediction
Event summary
- Myriad Genetics presented four abstracts at the SGO Annual Meeting, April 10-13, 2026, in San Juan, Puerto Rico.
- Data from Myriad’s Precise MRD™ test showed a significant correlation between ctDNA fraction and ovarian cancer recurrence.
- The Myriad Collaborative Research Registry (MCRR) contains de-identified data from over 1.3 million participants.
- Studies using the MCRR explored genetic variant prevalence in endometrial and ovarian cancers, and the utility of universal hereditary cancer screening.
- Presentations included findings on Lynch syndrome gene association with ovarian cancer diagnosis and age at diagnosis.
The big picture
Myriad’s focus on MRD testing and leveraging its large patient registry underscores a broader trend in oncology towards personalized medicine and earlier detection of recurrence. The company’s ability to translate these research findings into commercially viable tests and secure reimbursement will be critical for sustained growth. The MCRR represents a significant asset, but its value is contingent on maintaining its scale and relevance within the evolving research landscape.
What we're watching
- Clinical Adoption
- The uptake of Precise MRD testing by oncologists will depend on reimbursement policies and demonstrated clinical utility beyond the presented data, potentially impacting Myriad’s revenue projections.
- Data Integrity
- The value of the MCRR is predicated on maintaining data quality and participant privacy, and any breaches or methodological concerns could erode trust and limit its research utility.
- Competitive Landscape
- Other diagnostic companies are developing similar ctDNA-based recurrence monitoring tests, and Myriad’s market share will be influenced by the performance and pricing of competing offerings.
Related topics